ライフサイエンスコーパス: oncology

1 part of the Alliance for Clinical Trials in Oncology).

2 ing the potential of tankyrase inhibitors in oncology.

3 ognized as a potential therapeutic target in oncology.

4 nts an important immunotherapeutic target in oncology.

5 y, 3) patient engagement, and 4) value-based oncology.

6 trated a potential role of aFP treatments in oncology.

7 infectious disease medicine, cardiology, and oncology.

8 utility of molecularly targeted therapies in oncology.

9 challenging malignancies to treat in all of oncology.

10 rd implementation of precision head and neck oncology.

11 for future combination approaches in immune-oncology.

12 the management of allergy in daily clinical oncology.

13 update the ASCO guideline for antiemetics in oncology.

14 argets for therapeutics and biomonitoring in oncology.

15 this strategy for rapid tracer discovery for oncology.

16 apeutic targets and prevention strategies in oncology.

17 le, has not undergone clinical evaluation in oncology.

18 ng at the vanguard of experimental agents in oncology.

19 both predominant challenges in head and neck oncology.

20 ar understanding of the disease in precision oncology.

21 rials of the Alliance for Clinical Trials in Oncology.

22 ctive, albeit toxic, therapeutic strategy in oncology.

23 side and outside of the Assembly on Thoracic Oncology.

24 ier to, early palliative care integration in oncology.

25 of imaging for therapy planning in radiation oncology.

26 at converge with the broader field of immuno-oncology.

27 c drug with broad applicability in pediatric oncology.

28 ong been a critical therapeutic challenge in oncology.

29 bling widespread implementation of precision oncology.

30 method to circumvent acquired resistance in oncology.

31 onsensus-based approach for use in precision oncology.

32 The oncology (1.3%; 95% CI, 0.0%-3.9%) and pediatric intensi

33 need were identified: 1) omics and precision oncology, 2) advancing interoperability, 3) patient enga

34 As we enter into an era of precision oncology, a more comprehensive awareness of the factors

35 ent-parent dyads of hospital-based pediatric oncology ambulatory clinics and inpatient units between

36 ted repurposing drugs initially developed in oncology and autoimmunity.

37 lanning (ACP) is increasingly implemented in oncology and beyond, but a definition of ACP and recomme

38 less, some national and international cardio-oncology and cardiac-imaging organisations recommend inc

39 ntific and clinical environment of pediatric oncology and drug development; we provide specific recom

40 ogy Group, the German Society for Paediatric Oncology and Haematology, and the Japanese Study Group f

41 Research, particularly in oncology and heart failure, has shown that PROs can be p

42 S methodology and its applications in hemato-oncology and immunology.

43 multinational group of experts in pediatric oncology and infectious diseases that includes a patient

44 Despite numerous applications in oncology and medical imaging in general, there is no con

45 veloping ATSs from registries and cohorts in oncology and other fields requiring sequential treatment

46 Purpose The early integration of oncology and palliative care (EIPC) improves quality of

47 To improve the response assessment in neuro-oncology and to standardize the criteria that are used f

48 ngoing national efforts to provide precision oncology and value-based care to cancer patients.

49 t medical need, particularly in the areas of oncology and virology.

50 ntiated left ventricular hypertrophy, cardio-oncology, aortic stenosis, and ischemic heart disease.

51 rget enrichment workflows, commonly used for oncology applications, and feasibility using PacBio sing

52 ful development and application of precision oncology approaches require robust elucidation of the ge

53 Theranostic approaches using these drugs in oncology are particularly interesting because antibodies

54 critical mass of transcriptomic data in the oncology arena having been reached, they are ever more a

55 The emergence of immuno-oncology as the first broadly successful strategy for me

56 rsonalized therapy is a major goal of modern oncology, as patient responses vary greatly even within

57 nel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected

58 ommittee of the American Society of Clinical Oncology (ASCO) believes that a proactive stance by the

59 ember 2016, the American Society of Clinical Oncology (ASCO) Board of Directors approved the ASCO Str

60 (ASCP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to conduct a sy

61 (AMP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to develop an e

62 relevant to the American Society of Clinical Oncology (ASCO) membership.

63 update the 2012 American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO) on th

64 e To update the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (SSO) guide

65 Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on

66 Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on

67 Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on

68 ryngology, plastics, oculoplastics, surgical oncology) at an academic tertiary care referral center f

69 ide easily accessible information to a broad oncology audience, as this may help ease the information

70 are given specific types of information from oncology-based care (eg, survivorship care plans), and n

71 urotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in th

72 monstrate that MiSL can accelerate precision oncology by identifying mutation-specific targets and bi

73 Many of these functions impinge upon oncology by influencing the efficacy and toxicity of PI3

74 emia Group B/Alliance for Clinical Trials in Oncology [CALGB/Alliance 70604]) showed that zoledronic

75 er to receive either early integrated PC and oncology care (n = 175) or usual care (n = 175) between

76 integration of palliative care into standard oncology care for all patients diagnosed with cancer.

77 cer has been recognised as a priority within oncology care for several decades.

78 C and called for its inclusion in paediatric oncology care, rigorous investigation has provided impor

79 cerLinQ and other rapid-learning systems for oncology care, we sought to evaluate perspectives of pat

80 e brought forth the promise of genome-driven oncology care.

81 ns have fueled recent gains in genome-driven oncology care.

82 ns is now essential for radiologists reading oncology cases.

83 dical providers from eight leading pediatric oncology centers across the United States and Canada com

84 ISTINE trial in 68 Translational Research In Oncology centres (hospitals and specialty cancer centres

85 e 3 trial (OAK) in 194 academic or community oncology centres in 31 countries.

86 meningiomas from ten European academic neuro-oncology centres to identify distinct methylation classe

87 actionation is gaining momentum in radiation oncology centres, enabled by recent advances in radiothe

88 147 oncology class waivers were confirmed for 89 drugs.

89 14, at a single, academic, multidisciplinary oncology clinic among women planning to undergo mastecto

90 itive breast cancer was referred to a cardio-oncology clinic for pre-cancer treatment cardiovascular

91 and radiotherapy as standards of care in the oncology clinic.

92 creatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline published on May 31

93 animously decided that four areas of current oncology clinical practice have serious, unmet health in

94 performed to compare IMRT with 3D-CRT in NRG Oncology clinical trial RTOG 0617, in which patients rec

95 severe pneumonitis and cardiac doses in NRG Oncology clinical trial RTOG 0617, which supports routin

96 a quantitative imaging package optimized for oncology clinical trial workflows.

97 l concerns about including children early in oncology clinical trials do not apply in the current sci

98 iated with lowering the age of enrollment on oncology clinical trials.

99 amine and modernize eligibility criteria for oncology clinical trials.

100 experts in genetics, medical and gynecologic oncology, clinical psychology, epidemiology, genomics, c

101 r profiling results is overwhelming for many oncology clinicians and researchers.

102 Purpose To provide guidance to oncology clinicians on how to use effective communicatio

103 To provide evidence-based recommendations to oncology clinicians, patients, family and friend caregiv

104 s Patients with breast cancer from community oncology clinics and age-matched noncancer controls comp

105 breast cancer who were treated in community oncology clinics report substantially more cognitive dif

106 updates to the American Society of Clinical Oncology/College of American Pathologists recommendation

107 tes to the 2007 American Society of Clinical Oncology/College of American Pathologists recommendation

108 et diabetes is of particular interest to the oncology community as the differentiation of new-onset d

109 ar imaging holds great promise for precision oncology, complementing tissue-based markers to guide mo

110 Only 40.0% of students reported any clinical oncology component to their institution's training, and

111 Little is known about how clinical oncology concepts are taught to PhD students or the most

112 after baseline measure completion, a regular oncology consultation was audio-recorded and a follow-up

113 ree survival by response assessment in neuro-oncology criteria.

114 However, to expand applications to oncology, critical limitations of current methods must b

115 study using the National Cancer Database, an oncology database representing patients from more than 1

116 k force of the European Association of Neuro-Oncology did a systematic review of the available scient

117 o-ophthalmology, medical genetics, and neuro-oncology) direct management decisions, the absence of a

118 factors with preferences for provider roles-oncology-directed care versus primary care provider (PCP

119 or more-displayed greater odds of preferring oncology-directed care-versus PCP-directed care-for thei

120 ogical role in a variety of inflammatory and oncology disorders and has long been considered an attra

121 For immuno-oncology drug development, immune activation is often ex

122 In an unbiased screening of an oncology drug library, we found that sorafenib activates

123 Care Excellence [NICE] and the pan-Canadian Oncology Drug Review [pCODR]).

124 To date, over 100 small-molecule oncology drugs have been approved by the FDA.

125 with PBD- and tubulysin-based ADC and immuno-oncology drugs that may increase clinical responses.

126 For oncology drugs that were approved by the US Food and Dru

127 In this Review, we retrospectively searched oncology drugs that were class waivered between June, 20

128 Purpose The high cost of oncology drugs threatens the affordability of cancer car

129 g design and has been used to progress three oncology drugs through clinical trials to FDA approval.

130 roenvironment, and could combine with immuno-oncology drugs to enhance antitumor activity.

131 ncluded in the FDA table, we selected the 22 oncology drugs with required genetic testing in their la

132 Combinations of ADCs with immuno-oncology drugs, including PD-1 or PD-L1 antibodies, OX40

133 Food and Drug Administration (FDA)-approved oncology drugs.

134 sing their institution's methods of clinical oncology education and their perspective on optimal appr

135 erspective on optimal approaches to clinical oncology education.

136 ling is a fundamental component of precision oncology, enabling the identification of genomic alterat

137 amework and the European Society for Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale (MCB

138 dataset, International Society of Paediatric Oncology European Neuroblastoma/High-Risk Neuroblastoma

139 ed the value of nearly all types of clinical oncology exposure significantly lower than did students.

140 burden facing participants in the precision oncology field.

141 cement of precision medicine in the clinical oncology field.

142 or biology, have enormous potential in neuro-oncology for disease detection, grading, and tumor delin

143 Implementation of precision oncology for these patients has been limited by incomple

144 t has been particularly challenging in neuro-oncology for which contrast enhancement serves as an imp

145 xane use ( P = .02), and Eastern Cooperative Oncology Group >/= 1 ( P = .01).

146 Methods The American College of Surgeons Oncology Group (ACOSOG) Z1031A trial enrolled postmenopa

147 The Children's Oncology Group (COG) AAML0431 trial consisted of 4 cycle

148 rize nearly 1,000 participants in Children's Oncology Group (COG) AML trials.

149 ents with de novo AML enrolled in Children's Oncology Group (COG) studies AAML0531, AAML03P1, and CCG

150 e 2 selection design trial of the Children's Oncology Group (COG; ANBL1221), patients had to have his

151 tology and Oncology (NOPHO), Dutch Childhood Oncology Group (DCOG), and Acute Myeloid Leukemia-Berlin

152 CIST version 1.1) and an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

153 ction adenocarcinoma, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, MET-

154 al brain therapy, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; (B)

155 Patients had to have an Eastern Cooperative Oncology Group (ECOG) score of 0-2 and a documented life

156 s (in 2012) of 271 deaths in the Gynecologic Oncology Group (GOG) 240 trial.

157 se overall survival in the Radiation Therapy Oncology Group (RTOG) 0617 study.

158 olumes (CTVs) based on the Radiation Therapy Oncology Group (RTOG) guidelines cover (68)Ga-PSMA-11 PE

159 years and older from participating Southwest Oncology Group (SWOG) and National Clinical Trial Networ

160 Patients and Methods Southwest Oncology Group (SWOG) S0518, a phase III study conducted

161 ed in a previously reported trial (Southwest Oncology Group 9346) of PSA </= 0.2, > 0.2 to 4, and > 4

162 good performance status (Eastern Cooperative Oncology Group [ECOG] performance status 0-1).

163 radiotherapy (NRG Oncology Radiation Therapy Oncology Group [RTOG] 0129 and 0522).

164 This analysis of patients in the Children's Oncology Group A3973 study evaluated the impact of exten

165 tion (GO arm, n = 408) as per the Children's Oncology Group AAML0531 trial.

166 Purpose The Children's Oncology Group AAML0631 trial for newly diagnosed pediat

167 tion schema was incorporated into Children's Oncology Group B-cell ALL (B-ALL) clinical trials.

168 induction as part of the Eastern Cooperative Oncology Group high-dose IFN regimen is not better than

169 participants at 38 participating Children's Oncology Group hospitals in the USA and Canada.

170 ne treatment; and had an Eastern Cooperative Oncology Group performance score of 0-2.

171 es indicate worse pain), Eastern Cooperative Oncology Group performance status (range, 0-4; higher sc

172 iomarker assessment, and Eastern Cooperative Oncology Group performance status 0 or 1, among other cr

173 ble, nonsarcomatoid MPM (Eastern Cooperative Oncology Group performance status 0 to 1), stratified by

174 d age 18 years or older, Eastern Cooperative Oncology Group performance status 0-1, metastatic or loc

175 , symptomatic dysphagia, Eastern Cooperative Oncology Group performance status 0-2, and adequate haem

176 [1.02-1.20]; p=0.0188), Eastern Cooperative Oncology Group performance status 3-4 (2.92 [2.13-3.93];

177 d 18 years or older with Eastern Cooperative Oncology Group performance status of 0 or 1 and measurab

178 ged >/=18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and who had

179 r than 18 years, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequat

180 e end-organ function, an Eastern Cooperative Oncology Group performance status of 0 or 1, life expect

181 of standard therapy, and Eastern Cooperative Oncology Group performance status of 0 or 1.

182 Solid Tumors, and had an Eastern Cooperative Oncology Group performance status of 0 or 1.

183 ated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were int

184 Patients with mCRPC and Eastern Cooperative Oncology Group performance status of 0 to 2 were randoml

185 hormone receptor status, Eastern Cooperative Oncology Group performance status of 0-1, and adequate b

186 herapy was available, an Eastern Cooperative Oncology Group performance status of 0-1, and measurable

187 small-cell lung cancer, Eastern Cooperative Oncology Group performance status of 0-2, and adequate p

188 were asymptomatic, with Eastern Cooperative Oncology Group performance status of 0-2, and did not ha

189 , and the patient had an Eastern Cooperative Oncology Group performance status of 0.

190 least aged 18 years, had Eastern Cooperative Oncology Group performance status of 1 or less, and had

191 8 years or older, had an Eastern Cooperative Oncology Group performance status of 1 or less, had adeq

192 the left costal margin), Eastern Cooperative Oncology Group performance status of 2 or less, and life

193 positive tumours, had an Eastern Cooperative Oncology Group performance status of 2 or less, and rece

194 ts with stage III NSCLC (Eastern Cooperative Oncology Group performance status, 0 to 1) received dose

195 g lactate dehydrogenase, Eastern Cooperative Oncology Group performance status, age, and disease stag

196 by geographical region, Eastern Cooperative Oncology Group performance status, macrovascular invasio

197 metastatic melanoma, and Eastern Cooperative Oncology Group performance status.

198 a In Solid Tumors v1.1), Eastern Cooperative Oncology Group performance statuses of 0 or 1, and avail

199 3a follicular lymphoma; Eastern Co-operative Oncology Group performance statuses of 0-2; bidimensiona

200 mosomes 1p and 16q treated in the Children's Oncology Group protocol AREN0532.

201 ron (IFN) as part of the Eastern Cooperative Oncology Group regimen compared with observation (OBS) i

202 visceral metastases, and Eastern Cooperative Oncology Group score.

203 tribution, infiltration, Eastern Cooperative Oncology Group status, AFP level, and PVT extent.

204 or sex, cT and cN stage, Eastern Cooperative Oncology Group status, Charlson comorbidity score, treat

205 ower than 100 ng/dL, and Eastern Cooperative Oncology Group status.

206 toxicity as defined by the Radiation Therapy Oncology Group was compared between the control and expe

207 results of the American College of Surgeons Oncology Group Z0011 (ACOSOG Z0011) trial were first rep

208 ood Liver Tumours Strategy Group, Children's Oncology Group, the German Society for Paediatric Oncolo

209 luding patients from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Net

210 e National Clinical Trials Network-Southwest Oncology Group.

211 The European Association for Neuro-Oncology guideline provides recommendations for the clin

212 rituximab-containing salvage therapy from 12 oncology-haematology centres in Italy.

213 Although the main focus of immuno-oncology has been manipulating the adaptive immune syste

214 omic testing for somatic mutations in breast oncology has been slower than anticipated due to issues

215 r, most trials of novel molecular imaging in oncology have been small, single-center trials.

216 Recent advances in immuno-oncology have shown that the immune system can be activa

217 ogical disciplines." Genetics, cell biology, oncology, immunology, evolutionary mechanisms, neurobiol

218 of US Food and Drug Administration-approved oncology immunotherapy drugs with results posted at Clin

219 candidate with a broad application range in oncology, including treatment of brain tumors or CNS met

220 ble covalent inhibitor of FGFR1-4 for use in oncology indications.

221 sion of the theranostic principle into other oncology indications.

222 The second decade expanded PPC oncology investigation to include the entire cancer cont

223 application of IgE-derived drugs in clinical oncology is clear if the antitumor activity of MOv18 IgE

224 n this review will be paramount if Precision Oncology is ultimately to lead to clinical benefits.

225 ase 1 of a structured framework adapted from oncology) is available for all biomarkers, but their cli

226 d draw from key examples in the recent neuro-oncology literature to illustrate how these genomic appr

227 ion tomography (PET) detection tracer for an oncology marker.

228 erate ideal surrogate Abs for testing immuno-oncology mechanisms in vivo.

229 introduction of new staging technologies in oncology might misclassify true disease stage, spuriousl

230 Models in Translational Oncology (MiTO) database was developed as a unique Web p

231 IDO inhibitors may leverage not only immuno-oncology modalities but also chemotherapy and radiothera

232 Indications for PET were oncology (n=26), suspicion of prosthetic valve endocardi

233 Nordic Society for Pediatric Hematology and Oncology (NOPHO), Dutch Childhood Oncology Group (DCOG),

234 However, unlike in oncology or cardiology, it is unknown whether PROs are a

235 Whether existing cardio-oncology or imaging guideline recommendations will provi

236 As for other disciplines, such as oncology or rheumatology, we have to approach AD in a mo

237 g correlations between the microbiome of the oncology patient and infections occurring during chemoth

238 a retrospective institutional review of 433 oncology patients (203 men; mean age, 55 y), including a

239 Our findings suggest that pediatric oncology patients and families might benefit from, and a

240 Pediatric oncology patients experience a high degree of symptom-re

241 problem for many thrombocytopenic hematology/oncology patients in spite of platelet transfusions.

242 perceived barrier, especially for pediatric oncology patients, is the notion that patients and their

243 in 47 academic medical centres and community oncology practices in seven countries in North America a

244 t 217 academic medical centres and community oncology practices mainly in Europe, North America, and

245 e of surgical and noninvasive interventional oncology procedures by improving cancer detection capabi

246 Drug Administration Office of Hematology and Oncology Products in 2015.

247 ssive use of alcohol; * Provide education to oncology providers about the influence of excessive alco

248 onvened a multidisciplinary panel of medical oncology, psychiatry, nursing, hospice and palliative me

249 using platinum-based chemoradiotherapy (NRG Oncology Radiation Therapy Oncology Group [RTOG] 0129 an

250 CNS tumors, the Response Assessment in Neuro-Oncology (RANO) working group was established.

251 imal type 1 error rates and sample sizes for oncology RCTs.

252 were analyzed at a tertiary academic ocular oncology referral center using a customized bioinformati

253 the most notable examples of disparities in oncology related to racial/ethnic identity.

254 s study is likely to enhance PhD training in oncology-related disciplines.

255 d the tumor's biological features (precision oncology), requires a detailed knowledge of tumor biolog

256 Lectures on clinical oncology research topics were the most valuable type of

257 radiotherapy with or without cetuximab (NRG Oncology RTOG 0522) were included in this study, and 413

258 NRG Oncology RTOG 0525 specimens (n = 452) were analyzed for

259 PSCC randomly assigned to a third trial, NRG Oncology RTOG 9003.

260 The American Society of Clinical Oncology's first guideline in the 2013 Choosing Wisely (

261 sessment, the Neurologic Assessment in Neuro-Oncology scale was drafted.

262 Precision Oncology seeks to identify and target the mutation that

263 outcomes can be carried out in the surgical oncology setting.

264 ination in clinical studies, particularly in oncology settings, has garnered substantial recent inter

265 Balducci, International Society of Geriatric Oncology (SIOG) 1, SIOG2, and a latent class typology.

266 ategorized as general surgery (GS), surgical oncology (SO), and transplant (TS).

267 king group was composed of multidisciplinary oncology specialists in medicine, surgery, radiation the

268 and close collaboration between imaging and oncology specialists on a per-patient basis.

269 roach that includes primary care clinicians, oncology specialists, otolaryngologists, dentists, and o

270 Clinical Oncology (ASCO)-Society of Surgical Oncology (SSO) guideline for sentinel lymph node (SLN) b

271 nal approach to complement current precision oncology strategies.

272 patients to Alliance for Clinical Trials in Oncology systemic therapy breast cancer trials during 19

273 s gained increasing attention as a potential oncology target for small molecule inhibitors.

274 creening against the molecular chaperone and oncology target Hsp90, for which we obtain novel chemoty

275 bilities with which to attack this validated oncology target with small molecules.

276 r in surface protein expression than typical oncology targets of immunoPET, can serve as an imaging b

277 rovide unique information to guide precision oncology that includes measuring the regional expression

278 In oncology the inhibition of lymphangiogenesis is an estab

279 ines, especially in evolutionary biology and oncology, the developmental perspective is being reasser

280 d central nervous system, cardiovascular and oncology therapeutics.

281 upine inhibitors are thought to be promising oncology therapeutics.

282 on of phase I trials for A2AR antagonists in oncology, this approach has high translational potential

283 This analysis used all data received at NRG Oncology through April 12, 2015.

284 ing to a broad readership from the fields of oncology to virology.

285 uding those published in Journal of Clinical Oncology, to patients seen in their own clinical practic

286 Purpose The majority of randomized oncology trials are two-arm studies that test the effica

287 ren in appropriately designed adult clinical oncology trials is feasible and can be done in a way tha

288 omprehensive and clinical cancer centers for oncology trials using advanced imaging techniques, inclu

289 ted and are increasingly being used in neuro-oncology trials, although additional refinements will be

290 thway-targeted therapies have been tested in oncology trials, resulting in regulatory approval of one

291 ors have shown promising effects in clinical oncology trials.

292 ed and followed in a Spanish referral ocular oncology unit.

293 lesome, which is particularly detrimental in oncology where rearrangements play diagnostic and progno

294 s technology to improve outcomes in surgical oncology with attention to the various surgical procedur

295 Increase Racial and Ethnic Diversity in the Oncology Workforce is designed to enhance existing progr

296 move us closer to the vision of achieving an oncology workforce that reflects the demographics of the

297 ations affected by cancer and members of the oncology workforce who identify as SGM: (1) patient educ

298 Increase Racial and Ethnic Diversity in the Oncology Workforce.

299 r experts invited to the Omics and Precision Oncology Workgroup were tasked with the responsibility o

300 lementary workshops: the Omics and Precision Oncology Workshop in October 2016 and the Advancing Inte